← Leaderboards
Marta L Marthas
University Of California Davis
$7,401,608
Attributed
$7,401,608
Total exposure
28
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–10$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$7,401,608 · 28
By mechanism
R01$4,016,656 · 2
P51$2,836,633 · 24
R21$548,319 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of California Davis
Same institution · by research overlap
- Ian Manning Kennedy$2,544,709
- Bo L Lonnerdal$1,063,295
- Caroline J Chantry$1,155,686
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusVaccinesImmunologyModel Design /DevelopmentHematologyCommunicable DiseasesLymphatic SystemInflammationAidsMammaliaOral PharyngealMother /Infant Health CareImmunityMacaca MulattaAids VaccinesPediatric AidsInfantHiv VaccineNeonatalPreventResearch PersonnelTransmission ProcessOralOral Cavity
Grant awards (45)
REPLICATING VIRAL VECTOR AS NEONATAL VACCINE TO PREVENT ORAL SIV TRANSMISSION$152,094
P51 · FY2010 · RR · contact PI
REPLICATING VIRAL VECTOR AS NEONATAL VACCINE TO PREVENT ORAL SIV TRANSMISSION$146,580
P51 · FY2009 · RR · contact PI
Passive-Active Immunization Strategies Against Pediatric AIDS$610,378
R01 · FY2008 · AI · contact PI
REPLICATING VIRAL VECTOR AS NEONATAL VACCINE TO PREVENT ORAL SIV TRANSMISSION$168,995
P51 · FY2008 · RR · contact PI
VACCINE-ELICITED ANTIBODY DEPENDENT CELL CYTOTOXICITY IN PROTECTION AGAINST SIV$126,722
P51 · FY2008 · RR · contact PI
Passive-Active Immunization Strategies Against Pediatric AIDS$604,079
R01 · FY2007 · AI · contact PI
REPLICATING VIRAL VECTOR AS NEONATAL VACCINE TO PREVENT ORAL SIV TRANSMISSION$181,569
P51 · FY2007 · RR · contact PI
VACCINE-ELICITED ANTIBODY DEPENDENT CELL CYTOTOXICITY IN PROTECTION AGAINST SIV$139,671
P51 · FY2007 · RR · contact PI
Passive-Active Immunization Strategies Against Pediatric AIDS$604,000
R01 · FY2006 · AI · contact PI
REPLICATING VIRAL VECTOR AS NEONATAL VACCINE TO PREVENT ORAL SIV TRANSMISSION$156,653
P51 · FY2006 · RR · contact PI
POLIOVIRUS-SIV VACCINES IN PREGNANT AND INFANT MACAQUES$156,653
P51 · FY2006 · RR · contact PI
SIV VACCINES PROTECT INFANT RHESUS MACAQUES AGAINST ORAL SIVEXPOSURE$156,653
P51 · FY2006 · RR · contact PI
VACCINE-ELICITED ANTIBODY DEPENDENT CELL CYTOTOXICITY IN PROTECTION AGAINST SIV$117,515
P51 · FY2006 · RR · contact PI
SIV VACCINES PROTECT INFANT RHESUS MACAQUES AGAINST ORAL SIVEXPOSURE$207,141
P51 · FY2005 · RR
REPLICATING VIRAL VECTOR AS NEONATAL VACCINE TO PREVENT ORAL SIV TRANSMISSION$207,141
P51 · FY2005 · RR
POLIOVIRUS-SIV VACCINES IN PREGNANT AND INFANT MACAQUES$207,141
P51 · FY2005 · RR
Passive-Active Vaccine Strategies Against Pediatric AIDS$209,719
R21 · FY2004 · AI
SIV VACCINES PROTECT INFANT RHESUS MACAQUES AGAINST SIV$161,246
P51 · FY2004 · RR
POLIOVIRUS-SIV VACCINES IN PREGNANT AND INFANT MACAQUES$49,715
P51 · FY2004 · RR
VACCINE APPROACHES TO PREVENT HIV/AIDS IN CHILDREN$548,955
R01 · FY2003 · AI
SIV VACCINES PROTECT INFANT RHESUS MACAQUES AGAINST ORAL SIVVACCINE$360,702
P51 · FY2003 · RR
Vaccine to Prevent HIV Infection in Pregnancy &Newborns$169,300
R21 · FY2003 · AI
VACCINE TO PREVENT HIV INFECTION IN PREGNANCY AND NEWBORNS$140,442
P51 · FY2003 · RR
VACCINE APPROACHES TO PREVENT HIV/AIDS IN CHILDREN$527,814
R01 · FY2002 · AI
Vaccine to Prevent HIV Infection in Pregnancy &Newborns$169,300
R21 · FY2002 · AI
PASSIVE HYPERIMMUNE SERUM PROTECTS NEONATAL RHESUS AGAINST ORAL SIV INFECTION$0
P51 · FY2002 · RR
VACCINATION DURING PREGNANCY PROTECTS NEONATAL RHESUS AGAINST ORAL SIV$0
P51 · FY2002 · RR
VACCINATION OF NEONATAL RHESUS MACAQUES W/ LIVE ATTENUATED SHIV$0
P51 · FY2002 · RR
EARLY ANTIRETROVIRAL THERAPY TO PREVENT OR DELAY PEDIATRIC SIMIAN AIDS$0
P51 · FY2002 · RR
INFECTION OF RHESUS MACAQUES W/ CAEV FROM HUMAN BLOOD$0
P51 · FY2002 · RR
VACCINATION OF NEONATAL RHESUS MACAQUES W/ SIV DNA VACCINE$0
P51 · FY2002 · RR
CELLULAR IMMUNE RESPONSE TO SIV IN INFANT RHESUS MACAQUES$0
P51 · FY2002 · RR
HETEROSEXUAL TRANSMISSION OF SIV VIRAL VARIANTS$0
P51 · FY2002 · RR
VACCINATION OF NEONATAL RHESUS MACAQUES W/ SHIV PROVIRAL DNA$0
P51 · FY2002 · RR
VACCINE APPROACHES TO PREVENT HIV/AIDS IN CHILDREN$616,447
R01 · FY2001 · AI
HETEROSEXUAL TRANSMISSION OF SIV VIRAL VARIANTS$0
P51 · FY2001 · RR
VACCINATION OF NEONATAL RHESUS MACAQUES W/ SHIV PROVIRAL DNA$0
P51 · FY2001 · RR
PASSIVE HYPERIMMUNE SERUM PROTECTS NEONATAL RHESUS AGAINST ORAL SIV INFECTION$0
P51 · FY2001 · RR
VACCINATION DURING PREGNANCY PROTECTS NEONATAL RHESUS AGAINST ORAL SIV$0
P51 · FY2001 · RR
VACCINATION OF NEONATAL RHESUS MACAQUES W/ LIVE ATTENUATED SHIV$0
P51 · FY2001 · RR
EARLY ANTIRETROVIRAL THERAPY TO PREVENT OR DELAY PEDIATRIC SIMIAN AIDS$0
P51 · FY2001 · RR
INFECTION OF RHESUS MACAQUES W/ CAEV FROM HUMAN BLOOD$0
P51 · FY2001 · RR
VACCINATION OF NEONATAL RHESUS MACAQUES W/ SIV DNA VACCINE$0
P51 · FY2001 · RR
CELLULAR IMMUNE RESPONSE TO SIV IN INFANT RHESUS MACAQUES$0
P51 · FY2001 · RR
VACCINE APPROACHES TO PREVENT HIV/AIDS IN CHILDREN$504,983
R01 · FY2000 · AI